Which Pharmaceutical ETF Is Better, VanEck's PPH or Invesco's PJP?
Compare portfolio concentration, risk profiles, and long-term growth as these two pharma ETFs take different approaches to capturing sector opportunity.
Overview
The VanEck Pharmaceutical ETF (NASDAQ:PPH) offers a more cost-efficient entry point and higher income potential, while the Invesco Pharmaceuticals ETF (NYSEMKT:PJP) has recently demonstrated stronger price appreciation for investors seeking sector momentum.
These exchange-traded funds both target the U.S. pharmaceutical space, but they differ significantly in their construction and cost structures. While both funds capture the industry focus on drug development and research, their varying concentration levels and fees can lead to diverging outcomes for long-term shareholders.
Details
Beta measures price volatility relative to the S&P 500; beta is calculated from five-year monthly returns. The 1-yr return represents total return over the trailing 12 months. Dividend yield is the trailing-12-month distribution yield.
Source
Originally published at www.fool.com.